Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Provence Technologies Increases its Capital to EUR One Million

Published: Thursday, September 06, 2012
Last Updated: Thursday, September 06, 2012
Bookmark and Share
Underpinned by a stronger financial structure, the company will develop new projects for rehabilitating compounds of proven therapeutic potential.

Provence Technologies announces today that it has increased its capital by EUR 800,000 to EUR one million through a transfer from reserves. The company has greatly strengthened its financial structure since it was founded in 1998 and has succeeded in creating a solid shareholder base.
“We are particularly happy about this capital increase, which confirms our shareholders’ confidence in the future of Provence Technologies,” said Christophe Baralotto, the company’s CFO. “For all our partners, suppliers and clients, the increase is a guarantee of sustainability.”
Provence Technologies combines a traditional CRO (contract research organization) business for clients in the pharmaceutical, agrochemical and cosmetics industries with a high-value-added research activity based on its innovative technologies. Thanks to this balanced business model, the company has funded its research programs through its fee-for-service activities and has thus created a virtuous circle, with revenues derived from its own products. Provence Technologies is thus pushing ahead with research and development programs focused on compounds which are known for their high therapeutic potential but which have been neglected or abandoned up to now because of poor quality.
“The increased capital will enable Provence Technologies to support its growth strategy and fully develop its R&D programs,” said the company’s chairman, Michel Feraud. “Since it was founded, our company has sought, among other projects, to uncover the therapeutic potential of abandoned compounds, as it did with methylene blue. We want to continue down this path, which not only creates value for the company but also gives patients the benefit of these drugs.”
To carry this R&D strategy forward, two new researchers will join Provence Technologies at the end of 2012. The company is also planning to move into a new 1,600 square meter building in the Chateau-Gombert technology park in Marseille in 2013.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Provence Technologies and NexGenix Announce Successful Lead Compound Development
Both companies have been collaborating on the synthesis optimization and pre industrialization of innovative molecule targeting Hsp90.
Wednesday, July 06, 2011
Scientific News
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Fighting Pain with Ketamine
Researchers at the Texas A&M Health Science Center are using ketamine, a drug that already exists as an anesthetic, to treat pain.
Possible New Treatment for Neurodegenerative Diseases Found
Researchers at the University of Liverpool have found that a well-established anti-epileptic drug could also be used as a treatment for neurodegenerative diseases.
Breast Cancer Drug Beats Superbug
Tamoxifen helps white blood cells clear multidrug-resistant bacteria in lab and mouse studies.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos